牛牛AI助理已提取核心訊息
Todd Franklin Watanabe, associated with Arcutis Biotherapeutics, completed a sale of 14,903 shares of common stock on March 4, 2024. The transaction was executed at a price of $11.1212 per share, resulting in a total sale value of approximately $165,739.24. Following the sale, Watanabe directly holds 874,533 shares of the company. Additionally, Watanabe has indirect ownership of 231,140 shares through trusts and an LLC. The sale was conducted in the open market.
Todd Franklin Watanabe, associated with Arcutis Biotherapeutics, completed a sale of 14,903 shares of common stock on March 4, 2024. The transaction was executed at a price of $11.1212 per share, resulting in a total sale value of approximately $165,739.24. Following the sale, Watanabe directly holds 874,533 shares of the company. Additionally, Watanabe has indirect ownership of 231,140 shares through trusts and an LLC. The sale was conducted in the open market.
與Arcutis Biotherapeutics有聯繫的渡邊託德·富蘭克林於2024年3月4日完成了14,903股普通股的出售。該交易以每股11.1212美元的價格執行，總銷售價值約爲165,739.24美元。出售後，渡邊直接持有該公司874,533股股份。此外，渡邊通過信託和有限責任公司間接擁有231,140股股份。此次出售是在公開市場上進行的。
與Arcutis Biotherapeutics有聯繫的渡邊託德·富蘭克林於2024年3月4日完成了14,903股普通股的出售。該交易以每股11.1212美元的價格執行，總銷售價值約爲165,739.24美元。出售後，渡邊直接持有該公司874,533股股份。此外，渡邊通過信託和有限責任公司間接擁有231,140股股份。此次出售是在公開市場上進行的。
有用
沒用